Research across Migraine
Related studies from across the Migraine family.
11 trials tracked for migraine with or without aura: 9 in phase 3 or 4 and 9 with published results. The most-cited published study has 396 citations.
Showing the 11 most-cited and recently-updated of 11 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Rimegepant has demonstrated statistically significant improvements in acute migraine symptoms at 2 hours post-dose. Specifically, trials showed significantly higher rates of pain freedom compared to placebo across multiple studies [2, 3, 5]. Additionally, Rimegepant was associated with significantly higher rates of freedom from the most bothersome symptom (MBS) and photophobia [2, 5]. One trial also reported a low incidence of liver enzyme elevations (AST/ALT > 3x ULN concurrent with total bilirubin > 2x ULN) during treatment 6.
Ubrogepant demonstrated statistically significant improvements in pain freedom at 2 hours post-dose compared to placebo across two trials [7, 8]. While results for the absence of the most bothersome symptom (MBS) were not statistically significant in one trial 7, they were significantly higher than placebo in another 8. Furthermore, Ubrogepant showed a statistically significant increase in pain relief at 2 hours post-dose compared to placebo 8.
Atogepant demonstrated a statistically significant reduction in mean monthly migraine days (migraine/probable migraine headache days) over a 12-week treatment period 4. It also resulted in a statistically significant reduction in mean monthly headache days during the same period 4. Lasmiditan 50 mg showed statistically significant results for both pain freedom and freedom from the most bothersome symptom at 2 hours post-dose 10.
AI synthesis of 6 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
Related studies from across the Migraine family.